Theratechnologies Inc.

TH

CA88338H7040

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 21:00:00 23/05/2024 BST			5-day change	1st Jan Change
1.71 ^CAD	-2.84%		-4.47%	-20.09%

05-23	Theratechnologies Up Near 5% In US After Hours On Data Related To Its Lead Investigational Peptide Drug Conjugate Candidate	MT
05-23	Theratechnologies Brief: Says Sudocetaxel Zendusortide ASCO 2024 Presentation "Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors"	MT

Theratechnologies Inc. Announces Frank Holler as Chair of the Board of Directors

May 09, 2024 at 09:30 pm

Theratechnologies Inc. announced that Frank Holler will now act as Chair of the Board of Directors of the Company.

Latest news about Theratechnologies Inc.

Theratechnologies Up Near 5% In US After Hours On Data Related To Its Lead Investigational Peptide Drug Conjugate Candidate	05-23	MT
Theratechnologies Brief: Says Sudocetaxel Zendusortide ASCO 2024 Presentation "Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors"	05-23	MT
Theratechnologies Inc. Announces Frank Holler as Chair of the Board of Directors	05-09	CI
Transcript : Theratechnologies Inc. - Shareholder/Analyst Call	05-09
Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision	04-10	MT
Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug	04-10	MT
Transcript : Theratechnologies Inc., Q1 2024 Earnings Call, Apr 10, 2024	04-10
Theratechnologies Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024	04-10	CI
Theratechnologies Brief: Citing Acceleration of Phase 1 trial of sudocetaxel zendusortide in advanced ovarian cancer with enrollment of next cohort of patients underway at higher dose level	04-10	MT
Theratechnologies Brief: FY2024 revenue guidance confirmed between US$87-$90 million and an Adjusted EBITDA in the range of $13-15 million	04-10	MT
Theratechnologies Brief: Q1 2024 consolidated revenue of US$16.2 Million; Says Report marks third consecutive quarter of near-flat-to-positive Adjusted EBITDA	04-10	MT
Theratechnologies Inc. Re-Affirms Earnings Guidance for the Fiscal Year 2024	04-10	CI
North American Morning Briefing : Traders Await -2-	04-10	DJ
Theratechnologies Inc. Preclinical Data Presentation At AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology? Oncology Platform	04-08	CI
Theratechnologies Inc. Appoints Elina Tea to its Board of Directors and as Member of the Company's Audit Committee	04-05	CI
Theratechnologies To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform	03-28	MT
Theratechnologies Brief: To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform	03-28	MT
Theratechnologies Inc. Announces That It Will Phase Down Its Preclinical Oncology Research Activities	03-22	CI
Theratechnologies to Phase Down Preclinical Oncology Research Program	03-22	MT
Theratechnologies to Wind Down Preclinical Research, Focus on Ovarian Cancer Study	03-22	MT
Theratechnologies Inc. Appoints Jordan Zwick to Its Board of Directors and as Member of the Audit Committee	03-21	CI
Theratechnologies Initiates Higher Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer	03-21	MT
Theratechnologies Inc. Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer	03-21	CI
Theratechnologies Inc. Announces Board Changes	02-29	CI
Theratechnologies Down 30% In US Premarket -- Receives Refusal To File Letter From FDA	02-27	MT

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

Sector

Pharmaceuticals

Calendar

01/06/2024 - American Society of Clinical Oncology Annual Meeting - Abstract No - 3081

More about the company

Income Statement Evolution

More financial data

Ratings for Theratechnologies Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.71 CAD

Average target price

8 CAD

Spread / Average Target

+367.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
THERATECHNOLOGIES INC.	-20.09%	59.19M
CSL LIMITED	-2.17%	89.22B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	40.49B
BIOGEN INC.	-15.73%	32.79B
UCB	+64.13%	26.23B
BIOMARIN PHARMACEUTICAL INC.	-21.28%	14.52B
INCYTE CORPORATION	-8.50%	13.09B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.07%	11.6B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.06%	11.5B
SWEDISH ORPHAN BIOVITRUM AB	+4.94%	8.82B

Biopharmaceuticals